Neurizon Therapeutics Limited announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its lead investigational drug, NUZ-001. This decision marks a pivotal regulatory milestone for Neurizon and the ALS community, clearing the way for Phase 2/3 development of NUZ-001 as part of the HEALEY ALS Platform Trial, expected to commence Fourth Quarter CY2025. Opening an IND for a platform molecule establishes a regulatory foundation that not only accelerates the development of the first candidate but also streamlines future programs. By creating a validated framework for safety, manufacturing, and clinical design, it reduces regulatory risk, shortens timelines, and enables efficient expansion into new indications.
In this case, the IND is further strengthened by the robust and comprehensive package of preclinical safety data and the detailed manufacturing and quality information secured through licensing agreement with Elanco. These resources enhance confidence in the platform's readiness for clinical development and reinforce its potential as a therapeutic platform with broad applicability, offering both strategic flexibility and long-term commercial value. Next steps: With IND now active, Neurizon anticipates Mass General Hospital (MGH) filing a protocol amendment to their IND for the HEALEY ALS Platform trial to incorporate specific protocol regimen early in the coming weeks.
Neurizon expects to initiate patient enrollment in the HEALEY ALS Platform trials in fourth quarter of 2022. Together, these milestones advance Neurizon's mission to accelerate patient access to innovative therapies, create long-term value for shareholders, and establish NUZ-001 as a potential effective treatment for ALS. This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
